

Danilon equidos 1.5 g Granules for horses and ponies

Authorised

- Suxibuzone

Product identification

Medicine name:

Danilon equidos 1.5 g Granules for horses and ponies

Danilon equidos 1,5 g/10 g Granulat

Active substance:

Suxibuzone

Target species:

Horse

Horse (pony)

Route of administration:

In-feed use

Product details

Active substance and strength:

Suxibuzone

1.50 gram(s) / 10.00 gram(s)

Pharmaceutical form:

Granules

Withdrawal period by route of administration:

In-feed use:

-

Horse

- Meat and offal. no withdrawal period

Not to be used in animals intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation.

- Milk. no withdrawal period

Not to be used in animals intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation.

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QM01AA90

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Poland

Package description:

(ID2) 600 gram: Box with 60 Beutel (paper; aluminium; polyethylene) each with 10 gram

(ID1) 180 gram: Box with 18 Beutel (paper; aluminium; polyethylene) each with 10 gram

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Ecuphar Veterinaria S.L.U.

Marketing authorisation date:

28/11/2011

Manufacturing sites for batch release:

Esteve Pharmaceuticals S.A.

Responsible authority:

Office For Registration Of Medicinal Products Medical Devices And Biocidal Products

Authorisation number:

2156

Date of authorisation status change:

28/11/2011

Reference member state:

Germany

Procedure number:

DE/V/0192/001

Concerned member states:

Austria Belgium Czechia Denmark Estonia Hungary Iceland Latvia Lithuania
Norway Poland Romania Slovakia Slovenia United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet